Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Non-blanching rash and purpura assessment

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Purpura with systemic illness

A rapidly evolving non-blanching eruption with fever, altered behaviour, neck stiffness, limb pain, cold extremities, prolonged capillary refill, hypotension, breathing difficulty or reduced urine can signal meningococcal disease, sepsis or disseminated coagulation before shock is established.

Action: Use an immediate ABCDE assessment, call emergency transport or the resuscitation team, obtain cultures and bloods only if they do not delay care, and start age-appropriate parenteral antimicrobial and sepsis treatment through the current local pathway; isolate and notify suspected meningococcal disease as required.

Synopsis

Triage a non-blanching eruption without delay, describe purpura accurately across skin tones, distinguish infection, bleeding, inflammation and occlusion, and direct immediate tests and treatment by physiological risk.

  • Non-blanching means colour remains when firm pressure displaces blood from nearby capillaries; it describes extravasated blood or fixed vascular material, not a diagnosis.
  • Inspect the whole skin in good light, including conjunctivae, mouth, palms, soles and pressure areas; in brown or black skin, petechiae may be clearer on paler mucosa or by side lighting and palpation.
  • Never use a reassuring glass test to overrule an unwell patient: early meningococcal disease may have a blanching, sparse or absent rash, and deterioration can be fast.
  • Petechiae are pinpoint lesions, purpura are larger patches and ecchymoses are bruise-sized; more important bedside distinctions are flat versus palpable and round versus angular retiform morphology.
  • Fever, toxicity or rapidly multiplying lesions demands immediate sepsis and meningococcal assessment before a dermatological differential or biopsy.
  • Flat petechiae with mucosal bleeding favour platelet failure; large ecchymoses and deep bleeding suggest coagulation defects; palpable crops suggest inflamed small vessels.
  • Branching retiform purpura, cold skin, severe pain or necrosis indicates vascular occlusion or tissue ischaemia and needs urgent vascular, haematology, renal or dermatology input.
  • First-line tests in a stable unexplained presentation are FBC with film, coagulation and fibrinogen, renal and liver profiles, CRP and urinalysis, then phenotype-directed infection, haemolysis, autoimmune or clonal testing.
  • Record onset, speed, pain, fever, medicines, infections, bleeding sites and distribution and photograph with consent; do not erase a dangerous trajectory by calling the lesions bruises.

Key red flags

Toxic appearance, rapid lesion spread, fever or hypothermia, altered consciousness, severe limb or abdominal pain, meningism, respiratory compromise, hypotension, delayed refill, oliguria, mucosal bleeding, neurological deficit, pregnancy or immunosuppression requires same-day hospital assessment.

Retiform purpura

Angular branching non-blanching patches map an obstructed vessel network; pain, coolness, ulceration or black necrosis signals threatened tissue.

Septic trajectory

Rapid spread with fever, limb pain, reduced responsiveness, poor perfusion or respiratory change is an emergency even if lesions are few or partially blanching.

Investigation priorities

01
Immediate observations and perfusionFirst step

Detect sepsis, shock and limb-threatening vascular compromise before diagnostic sampling.

Management branches

Emergency first sequenceTreat physiology before naming purpura

Non-blanching lesions accompany fever, toxicity, rapid progression or impaired perfusion.

  1. Start ABCDE assessment, record the evolution and summon senior emergency help while checking meningism, limb pain, shock, bleeding and a likely infectious source.
  2. Obtain cultures, lactate, FBC, coagulation, renal and liver tests if this causes no treatment delay and begin parenteral antibiotics and sepsis resuscitation through the current age-specific protocol.
  3. Reassess within minutes, document lesion spread and perfusion and coordinate critical care, infection, haematology or vascular support according to shock, coagulopathy and tissue threat.
First-line stable assessmentSeparate leakage, inflammation and occlusion

The person is physiologically stable and the eruption is not rapidly advancing.

  1. Inspect all skin and mucosa, press representative lesions, palpate elevation and temperature and examine pulses, joints, abdomen, nerves and cardiorespiratory system.
  2. Build a timed history of infection, medicines, vaccines, trauma, bleeding, travel, pregnancy, systemic symptoms and previous episodes and photograph the distribution with consent.
  3. Request FBC and film, coagulation and fibrinogen, renal and liver profiles, inflammatory markers and urine, expanding tests only after the initial phenotype is clear.
Open full textbook →Answer 2 questions
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG240 bacterial meningitis and meningococcal diseaseRecognition, emergency investigations, antimicrobials, transfer and follow-up across age groups.
  • NICE NG143 fever in under fivesRisk assessment and urgent action for non-blanching rash and suspected meningococcal disease in young children.
  • NHS meningitis symptomsAccessible warning symptoms and explicit advice not to wait for every feature or a rash.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom